Paying users zone. Data is covered by hidden.

  • Get to Celgene Corp. for $13.99, or

  • get to whole website for at least 3 months from $49.99.

Microsoft Excel LibreOffice Calc


Price to FCFE (P/FCFE)

Difficulty: Intermediate


Free Cash Flow to Equity (FCFE)

Celgene Corp., FCFE calculation

USD $ in millions

Microsoft Excel LibreOffice Calc
12 months ended Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Net income hidden hidden hidden hidden hidden
Net noncash charges hidden hidden hidden hidden hidden
Change in current assets and liabilities, excluding the effect of acquisitions hidden hidden hidden hidden hidden
Net cash provided by operating activities hidden hidden hidden hidden hidden
Capital expenditures hidden hidden hidden hidden hidden
Proceeds from short-term borrowing hidden hidden hidden hidden hidden
Principal repayments on short-term borrowing hidden hidden hidden hidden hidden
Proceeds from the issuance of long-term debt hidden hidden hidden hidden hidden
Repayments of long-term debt hidden hidden hidden hidden hidden
Free cash flow to equity (FCFE) hidden hidden hidden hidden hidden

Based on: 10-K (filing date: 2018-02-07), 10-K (filing date: 2017-02-10), 10-K (filing date: 2016-02-11), 10-K (filing date: 2015-02-20), 10-K (filing date: 2014-02-13).

Item Description The company
FCFE Free cash flow to equity is the cash flow available to Celgene Corp.'s equity holders after all operating expenses, interest, and principal payments have been paid and necessary investments in working and fixed capital have been made. Celgene Corp.'s FCFE declined from 2015 to 2016 but then slightly increased from 2016 to 2017.

Price to FCFE Ratio, Current

Celgene Corp., current P/FCFE calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
No. shares of common stock outstanding hidden
Selected Financial Data (USD $)
Free cash flow to equity (FCFE) (in millions) hidden
FCFE per share hidden
Current share price (P) hidden
Ratio
P/FCFE hidden
Benchmarks
P/FCFE, Competitors
Abbott Laboratories hidden
AbbVie Inc. hidden
Allergan PLC hidden
Amgen Inc. hidden
Biogen Inc. hidden
Bristol-Myers Squibb Co. hidden
Eli Lilly & Co. hidden
Gilead Sciences Inc. hidden
Johnson & Johnson hidden
Merck & Co. Inc. hidden
Pfizer Inc. hidden
Regeneron Pharmaceuticals Inc. hidden
P/FCFE, Sector
Pharmaceuticals & Biotechnology hidden
P/FCFE, Industry
Health Care hidden

Based on: 10-K (filing date: 2018-02-07).

If company P/FCFE is lower then the P/FCFE of benchmark then company is relatively undervalued.

Otherwise, if company P/FCFE is higher then the P/FCFE of benchmark then company is relatively overvalued.


Price to FCFE Ratio, Historical

Celgene Corp., historical P/FCFE calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
No. shares of common stock outstanding1 hidden hidden hidden hidden hidden
Selected Financial Data (USD $)
Free cash flow to equity (FCFE) (in millions)2 hidden hidden hidden hidden hidden
FCFE per share4 hidden hidden hidden hidden hidden
Share price1, 3 hidden hidden hidden hidden hidden
Ratio
P/FCFE5 hidden hidden hidden hidden hidden
Benchmarks
P/FCFE, Competitors
Abbott Laboratories hidden hidden hidden hidden hidden
AbbVie Inc. hidden hidden hidden hidden hidden
Allergan PLC hidden hidden hidden hidden hidden
Amgen Inc. hidden hidden hidden hidden hidden
Biogen Inc. hidden hidden hidden hidden hidden
Bristol-Myers Squibb Co. hidden hidden hidden hidden hidden
Eli Lilly & Co. hidden hidden hidden hidden hidden
Gilead Sciences Inc. hidden hidden hidden hidden hidden
Johnson & Johnson hidden hidden hidden hidden hidden
Merck & Co. Inc. hidden hidden hidden hidden hidden
Pfizer Inc. hidden hidden hidden hidden hidden
Regeneron Pharmaceuticals Inc. hidden hidden hidden hidden hidden
P/FCFE, Sector
Pharmaceuticals & Biotechnology hidden hidden hidden hidden hidden
P/FCFE, Industry
Health Care hidden hidden hidden hidden hidden

Based on: 10-K (filing date: 2018-02-07), 10-K (filing date: 2017-02-10), 10-K (filing date: 2016-02-11), 10-K (filing date: 2015-02-20), 10-K (filing date: 2014-02-13).

1 Data adjusted for splits and stock dividends.

2 See Details »

3 Close price on the filing date of Celgene Corp.'s Annual Report.

2017 Calculations

4 FCFE per share = FCFE ÷ No. shares of common stock outstanding
= hidden ÷ hidden = hidden

5 P/FCFE = Share price ÷ FCFE per share
= hidden ÷ hidden = hidden

Ratio Description The company
P/FCFE Price to free cash flow to equity is cash valuation indicator of stockholders' equity. Celgene Corp.'s P/FCFE ratio increased from 2015 to 2016 but then slightly declined from 2016 to 2017 not reaching 2015 level.